抗新型冠状病毒的小分子药物最新研究进展

doi:10.19803/j.1672-8629.20230357

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (9): 961-966.
DOI: 10.19803/j.1672-8629.20230357

抗新型冠状病毒的小分子药物最新研究进展

马瑞泽, 陈志海^*

首都医科大学附属北京地坛医院感染性疾病临床中心,北京 100015

收稿日期:2023-06-09 出版日期:2023-09-15 发布日期:2023-09-14
通讯作者: ^*陈志海,男,硕士,主任医师,感染性疾病。E-mail: chenzhihai0001@126.com。陈志海,主任医师,教授,博士生导师,长江学者奖励计划特聘教授。首都医科大学附属北京地坛医院感染性疾病临床中心主任,国家卫生健康委传染病标准专业委员会委员,中华预防医学会感染性疾病防控分会常务委员,中华医学会北京分会感染专业委员会副主任委员,北京中西医结合学会感染专业委员会主任委员。致力于各种急性传染病临床诊治研究30余年,作为国家卫生健康委、北京市卫生健康委专家参加全国各种重大传染病疫情处置。新冠肺炎疫情以来,作为国家专家组、市级专家组成员,始终奋战在一线参加患者救治及疫情处置。在新冠肺炎领域作为第一主编编著专著2部,参与2项国家重点研发计划,以第一作者或通讯作者身份发表中英文论文16 篇（SCI 6篇）,参与完成《北京市新型冠状病毒肺炎病例临床路径》第一版、第二版。
作者简介:马瑞泽,女,在读硕士,感染性疾病。
基金资助:
国家重点研发计划（2022YFF1203201）

The latest progress of small molecule anti-SARS-CoV-2 drugs

MA Ruize, CHEN Zhihai^*

Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

Received:2023-06-09 Online:2023-09-15 Published:2023-09-14

摘要/Abstract

摘要： 目的综述目前国内外主要小分子抗新型冠状病毒（SARS-CoV-2）药物的作用机制及临床疗效。方法针对SARS-CoV-2的分子结构及感染机制,从药物阻断病毒机制、药代动力学特征、临床治疗效果等方面对国内外批准上市的小分子药物进行论述总结。结果根据SARS-CoV-2目前的流行变异株特点,小分子药物以其特有的优势正表现出巨大潜力。其中,国内外以蛋白酶抑制剂和与依赖RNA的RNA聚合酶抑制剂为重点,抗SARS-CoV-2小分子新老药物的研发已取得重大进展。结论小分子抗SARS-CoV-2药物可作为防疫的有力武器,早期应用可有效改善临床症状,降低重症率、住院率和死亡率。

关键词: 新型冠状病毒, 感染, 小分子抗病毒药物, 临床试验

Abstract: Objective To study the main small molecule anti-SARS-CoV-2 drugs. Methods Aiming at the molecular structure and infection mechanism of SARS-CoV-2, we discussed and summarized the small molecule drugs from the aspects of blocking virus mechanism and clinical effect. Results According to the characteristics of the current variants of SARS-CoV-2, small molecule drugs were showing great potential with their unique advantages. Focusing on protease inhibitors and RNA-dependent RNA polymerase inhibitors, significant progress has been made in the research and development of new and old anti-SARS-CoV-2 small molecule drugs. Conclusions mall molecule anti-SARS-CoV-2 drugs can be used as a powerful weapon to fight the COVID-19 epidemic, and the early application of small molecule drugs can effectively improve clinical symptoms, reduce severe disease, hospitalization and mortality rate.

Key words: SARS-CoV-2, infection, small molecule drugs, clinical trials

中图分类号:

R978.7

马瑞泽, 陈志海. 抗新型冠状病毒的小分子药物最新研究进展[J]. 中国药物警戒, 2023, 20(9): 961-966.

MA Ruize, CHEN Zhihai. The latest progress of small molecule anti-SARS-CoV-2 drugs[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 961-966.

参考文献

[1] Johns Hopkins University. COVID-19 dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University (JHU)[EB/OL].(2023-03-10)[2023-03-10].https://coronavirus.Edu/map.htm.
[2] LU R, ZHAO X, LI J, et al.Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet, 2020, 395(10224): 565-574.
[3] KUMAR V, PARATE S, YOON S, et al.Computational simulations identified marine-derived natural bioactive compounds as replication inhibitors of SARS-CoV-2[J]. Front Microbiol, 2021, 12: 647295.
[4] HOFFMANN M, KLEINE-WEBER H, SCHROEDER S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2): 271-280.e8.
[5] CLAUSEN TM, SANDOVAL DR, SPLIID CB, et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2[J]. Cell, 2020, 183(4): 1043-1057.e15.
[6] KIRCHDOERFER RN, WARD AB. structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors[J]. Nat Commun, 2019, 10(1): 2342.
[7] FREITAS BT, DURIE IA, MURRAY J, et al.Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease[J]. ACS Infect Dis, 2020, 6(8): 2099-2109.
[8] Guidelines for the diagnosis and treatment of coronavirusdisease 2019(trial version ninth)[J]. Chinese Journal of Viral Diseases(中国病毒病杂志), 2022, 12(3): 161-169.
[9] ZHANG JL, LI YH, WANG LL, et al.Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients[J]. Signal Transduct Target Ther, 2021, 6(1): 414.
[10] SMITH DB, KALAYANOV G, SUND C, et al.The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4'-azidocytidine against hepatitis C virus replication: the discovery of 4'-azido-2'-deoxy-2'-fluorocytidine and 4'-azido-2'-dideoxy-2',2'-difluorocytidine[J]. J Med Chem, 2009, 52(9): 2971-2978.
[11] XU N, YANG J, ZHENG B, et al.The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses[J]. J Virol, 2020, 94(9): e00204-e00220.
[12] TAO L, LI Y, GUO X, et al.Synthesis and anti-CVB3 activity of 4-amino acid derivative substituted pyrimidine nucleoside analogues[J]. Bioorg Med Chem Lett, 2020, 30(1): 126770.
[13] WANG J, XU WF, JIN PF.The first domestic original drug for the treatment of COVID-19: Azvudine[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2022, 57(23): 2041-2044.
[14] YANG L, WANG Z.Bench-to-bedside: innovation of small molecule anti-SARS-CoV-2 drugs in China[J]. Eur J Med Chem, 2023, 257: 115503.
[15] VICENTI I, ZAZZI M, SALADINI F.SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19[J]. Expert Opin Ther Pat, 2021, 31(4): 325-337.
[16] GORDON CJ, TCHESNOKOV EP, SCHINAZI RF, et al.Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template[J]. J Biol Chem, 2021, 297(1): 100770.
[17] KABINGER F, STILLER C, SCHMITZOVÁ J, et al.Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis[J]. Nat Struct Mol Biol, 2021, 28(9): 740-746.
[18] PAINTER WP, HOLMAN W, BUSH JA, et al.Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2[J]. Antimicrob Agents Chemother, 2021, 65(5): e02428-20.
[19] AGOSTINI ML, PRUIJSSERS AJ, CHAPPELL JD, et al.Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance[J]. J Virol, 2019, 93(24): e01348-19.
[20] WAHL A, GRALINSKI LE, JOHNSON CE, et al.SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801[J]. Nature, 2021, 591(7850): 451-457.
[21] JAYK BERNAL A, GOMES DA SILVA MM, MUSUNGAIE DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients[J]. N Engl J Med, 2022, 386(6): 509-520.
[22] SINGH AK, SINGH A, SINGH R, et al.Molnupiravir in COVID-19: A systematic review of literature[J]. Diabetes Metab Syndr, 2021, 15(6): 102329.
[23] KHOO SH, FITZGERALD R, SAUNDERS G, et al.Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomized, placebo-controlled, double-blind, phase 2 trial[J]. Lancet Infect Dis, 2023, 23(2): 183-195.
[24] DONOVAN-BANFIELD I, PENRICE-RANDAL R, GOLDSWAIN H, et al.Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial[J]. Nat Commun, 2022, 13(1): 7284.
[25] ZHOU S, HILL CS, SARKAR S, et al.β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells[J]. J Infect Dis, 2021, 224(3): 415-419.
[26] BEIGEL JH, TOMASHEK KM, DODD LE, et al.Remdesivir for the treatment of COVID-19 - final report[J]. N Engl J Med, 2020, 383(19): 1813-1826.
[27] HUMENIUK R, MATHIAS A, KIRBY BJ, et al.Pharmacokinetic, pharmacodynamic, and drug-interaction profile of Remdesivir, a SARS-CoV-2 replication inhibitor[J]. Clin Pharmacokinet, 2021, 60(5): 569-583.
[28] ZHAO Z, ZHANG Q, GE ZR, et al.Giant progress in small molecule antiviral drugs for SARS-CoV-2[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(1): 1-6.
[29] GRUNDEIS F, ANSEMS K, DAHMS K, et al. Remdesivir for the treatment of COVID-19[J]. Cochrane Database Syst Rev, 2023, 1(1): CD014962.
[30] ADER F, BOUSCAMBERT-DUCHAMP M, HITES M, et al.Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial[J]. Lancet Infect Dis, 2022, 22(2): 209-221.
[31] LA TESSA A, MOTISI MA, MARSEGLIA GL, et al.Use of remdesivir in children with COVID-19 infection: a quick narrative review[J]. Acta Biomed, 2021, 92(S7): e2021524.
[32] WANG Z, YANG L, SONG XQ.Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase[J]. Front Immunol, 2022, 13: 1015355.
[33] NMPA Conditionally approved the marketing of the combined packaging of Xianotevir Tablets/Ritonavir Tablets and Remidvir Deuterate Hydrobromide Tablets, a treatment drug for COVID-19 infection [EB/OL].(2023-02-07)[2023-03-10]. https://www.nmpa.gov.cn/zhuanti/yqjzx/yqyjxd/20230129143814163.html.
[34] SHEN Y, AI J, LIN N, et al.An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants[J]. Emerg Microbes Infect, 2022, 11(1): 1518-1523.
[35] CAO Z, GAO W, BAO H, et al.VV116 versus Nirmatrelvir-Ritonavir for oral treatment of COVID-19[J]. N Engl J Med, 2023, 388(5): 406-417.
[36] QIAN HJ, WANG Y, ZHANG MQ, et al.Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects[J]. Acta Pharmacol Sin, 2022, 43(12): 3130-3138.
[37] HILGENFELD R.From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design[J]. FEBS J, 2014, 281(18): 4085-4096.
[38] ANAND K, ZIEBUHR J, WADHWANI P, et al.Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs[J]. Science, 2003, 300(5626): 1763-1767.
[39] SEVRIOUKOVA IF, POULOS TL.Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir[J]. Proc Natl Acad Sci U S A, 2010, 107(43): 18422-18427.
[40] Pfizer Inc. Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death[EB/OL]. (2021-12-14)[ 2023-03-10].https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results.
[41] Food and drug administration. Food and Drug Administration Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid[EB/OL]. (2022-01-18)[2023-03-10]. https://www.fda.gov/media/155050/download.
[42] HAMMOND J, LEISTER-TEBBE H, GARDNER A, et al.Oral Nirmatrelvir for high-risk, nonhospitalized adults with COVID-19[J]. N Engl J Med, 2022, 386(15): 1397-1408.
[43] DRYDEN-PETERSON S, KIM A, KIM AY, et al.Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. health system: a population-based cohort study[J]. Ann Intern Med, 2023, 176(1): 77-84.
[44] CHANG JB.Advances of oral small molecule drug for the treatment of COVID-19[J]. Bulletin of National Natural Science Foundation of China(中国科学基金), 2022, 36(4): 630-634.
[45] UNOH Y, UEHARA S, NAKAHARA K, et al.Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19[J]. Med Chem, 2022, 65(9): 6499-6512.
[46] URAKI R, KISO M, IIDA S, et al.Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2[J]. Nature, 2022,607(7917):119-127.
[47] SHIMIZU R, SONOYAMA T, FUKUHARA T, et al.Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults[J]. Antimicrob Agents Chemother, 2022, 66(10): e0063222.
[48] WANG F, XIAO W, TANG Y, et al.Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial[J]. Lancet Reg Health West Pac, 2023, 38: 100835.

抗新型冠状病毒的小分子药物最新研究进展

The latest progress of small molecule anti-SARS-CoV-2 drugs

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张敬升, 冀祖恩, 庞博, 徐英莉, 曹姗, 张宇, 孙绮悦, 孙静, 李舒冉, 张薇, 赵荣华, 崔晓兰. 宣肺败毒方治疗新冠病毒感染的中医学理论探讨及现代药理研究进展[J]. 中国药物警戒, 2024, 21(1): 55-58.
[2]	李舒冉, 郭姗姗, 冀祖恩, 张薇, 崔晓兰. 新型冠状病毒感染后认知功能障碍的研究现状[J]. 中国药物警戒, 2024, 21(1): 59-64.
[3]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[4]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[5]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.
[6]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.
[7]	史卜文, 李利寻, 谢雁鸣, 王志飞, 王淇. 真实世界喜炎平注射液治疗3846例细菌性肠道感染患者临床用药特征分析[J]. 中国药物警戒, 2023, 20(9): 1017-1021.
[8]	李婧, 徐烨, 刘冉佳, 潘晨, 崔向丽. 新型冠状病毒感染患者使用托珠单抗后发生不良反应的病例分析[J]. 中国药物警戒, 2023, 20(9): 1049-1053.
[9]	. 国家药品不良反应监测年度报告（2022年）[J]. 中国药物警戒, 2023, 20(6): 712-719.
[10]	范秀丛, 董晓慧, 陈丹霞, 鲍思蔚, 马雅斌. 1例妊娠期艰难梭菌感染伴尿路感染患者的药学监护[J]. 中国药物警戒, 2023, 20(5): 579-582.
[11]	黄少兰, 杨戈, 李薇. 注射用头孢他啶阿维巴坦联用注射用硫酸多黏菌素B致肾移植患者肌无力1例分析[J]. 中国药物警戒, 2023, 20(5): 583-584.
[12]	陈诚, 邓莉, 刘松青, 杜倩, 奚鑫. 重庆市2015年至2020年药源性过敏性休克报告分析[J]. 中国药物警戒, 2023, 20(4): 460-464.
[13]	包蕾, 耿子涵, 郭姗姗, 姚荣妹, 孙静, 崔晓兰. 热炎宁合剂对呼吸系统感染性炎症动物抗感染作用研究[J]. 中国药物警戒, 2023, 20(3): 241-247.
[14]	李舒冉, 郭姗姗, 崔晓兰. 单纯疱疹病毒I型与阿尔茨海默病相关性及中药抗单纯疱疹病毒I型感染研究进展[J]. 中国药物警戒, 2023, 20(3): 258-261.
[15]	杜莹, 谢雁鸣, 王连心, 耿洪娇, 李向杰. 真实世界连花清瘟胶囊（颗粒）适应证人群临床特征及联合用药分析[J]. 中国药物警戒, 2023, 20(3): 296-300.